Clinical Trials Browser

binimetinib × 90 days × Clear all

NCT05203172 2026-03-18

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

Other solid neoplasm

Solid Tumors

NCT05554367 2026-03-18

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05111561 2026-03-17

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1 Suspended

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04221438 2026-03-12

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Phase 2 Terminated

3 enrolled 11 charts

Lymphatic Metastasis, Melanoma

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

Melanoma, Skin Neoplasms

NCT05554354 2026-03-03

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase 2 Terminated

Anatomic Stage IV Breast Cancer AJCC v8

NCT04741997 2026-03-02

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Phase EARLY_PHASE1 Recruiting

Melanoma

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 1 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT03170206 2026-02-12

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Phase 1 Completed

Lung Neoplasms

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Skin Neoplasms

NCT05355701 2026-02-03

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1 Recruiting

CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2 Recruiting

DermatologicGastrointestinal

Uveal Melanoma, Melanoma, Colorectal Neoplasms

NCT05286788 2026-01-12

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Phase 2 Recruiting

Craniopharyngioma

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1/2 Terminated

34 enrolled 44 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05195632 2026-01-07

OCEANII

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms